Chemo for metastatic vulvar cancer with carboplatin and paclitaxel
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial studies how well carboplatin plus paclitaxel chemotherapy works for vulvar squamous cell cancer that has spread. It may help shrink tumors and control cancer growth in people who are not able to be fully treated with local surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older and can sign consent to join the study
- Your vulvar cancer has been confirmed as squamous cell type (from biopsy or scan)
- Your cancer has spread to areas outside the pelvis (metastatic, measurable disease)
- Your body is strong enough to do daily activities (performance status 0–2) and your blood, liver, and kidneys are working well enough for chemo
- You have not had radiation to the vulva, groin, or pelvis before
- If you could become pregnant, you have a negative pregnancy test and agree to follow study pregnancy rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy (carboplatin and paclitaxel) before surgery for certain cases of squamous cell vulvar cancer. It may help shrink the tumor and make surgery more effective.
This Phase 2 trial compares two treatment approaches for some women with vulvar squamous cell cancer: chemoradiation first, or chemotherapy first followed by surgery. The goal is to see which strategy works better or is safer for tumors that are hard to remove without major pelvic surgery.
This Phase 2 trial tests AK104 in people with recurrent or metastatic vulvar cancer that cannot be cured with surgery or strong radiation. It may help shrink tumors or slow growth, especially if you’ve already tried standard treatments or couldn’t tolerate them.
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
This Phase 2 study looks at how vulvar squamous cell cancer (SCC) spreads to the sentinel lymph node, and how findings may guide treatment. It focuses on specific early-stage tumor features and requires that cancer is found in the sentinel lymph node.
This trial tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for women with advanced vulvar cancer that cannot be surgically removed or has spread. The goal is to see if this combination can shrink or control the cancer.
Hear when a new Metastatic Squamous Cell Carcinoma of the Vulva trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.